{"data":{"ModuleTitle":{"label":"Module Title","value":"Company Description"},"CompanyName":{"label":"Company Name","value":"Psyence Biomedical Ltd."},"Symbol":{"label":"Symbol","value":"PBMWW"},"Address":{"label":"Address","value":"121 RICHMOND STREET WEST,PENTHOUSE SUITE, 1300, TORONTO, Ontario, M5H2K1, Canada"},"Phone":{"label":"Phone","value":"1-416-477-1708"},"Industry":{"label":"Industry","value":"Biotechnology: Pharmaceutical Preparations"},"Sector":{"label":"Sector","value":"Health Care"},"Region":{"label":"Region","value":"North America"},"CompanyDescription":{"label":"Company Description","value":"Psyence Biomedical Ltd. (Nasdaq: PBM) is the world's first life science biotechnology company focused on the development of botanical (nature derived, or non-synthetic) psilocybin-based psychedelic medicine to be listed on Nasdaq. The name 'Psyence' combines the words 'psychedelics' and 'science' to affirm Psyence Biomed's commitment to an evidence-based approach to innovation as it works to develop safe and effective, nature-derived psychedelic therapeutics to treat a broad range of mental health disorders. The Company is initially focused on mental health disorders in the context of Palliative Care."},"CompanyUrl":{"label":"Company Url","value":"https://psyencebiomed.com/"},"KeyExecutives":{"label":"Key Executives","value":[{"name":"Neil Maresky","title":"Chief Executive Officer & Director"}]}},"message":null,"status":{"rCode":200,"bCodeMessage":null,"developerMessage":null}}